Dakota Wealth Management Reduces Position in Zoetis Inc. (NYSE:ZTS)

Dakota Wealth Management lowered its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 24.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 83,558 shares of the company's stock after selling 27,705 shares during the quarter. Dakota Wealth Management's holdings in Zoetis were worth $16,492,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in ZTS. Enterprise Financial Services Corp increased its holdings in Zoetis by 2.3% during the first quarter. Enterprise Financial Services Corp now owns 2,446 shares of the company's stock worth $407,000 after buying an additional 55 shares during the last quarter. CreativeOne Wealth LLC raised its holdings in shares of Zoetis by 0.4% in the 2nd quarter. CreativeOne Wealth LLC now owns 12,833 shares of the company's stock valued at $2,210,000 after purchasing an additional 57 shares during the period. MJP Associates Inc. ADV lifted its stake in Zoetis by 4.8% in the 3rd quarter. MJP Associates Inc. ADV now owns 1,275 shares of the company's stock valued at $222,000 after purchasing an additional 58 shares during the last quarter. River Street Advisors LLC grew its holdings in Zoetis by 3.4% during the fourth quarter. River Street Advisors LLC now owns 1,757 shares of the company's stock worth $347,000 after purchasing an additional 58 shares during the period. Finally, Perigon Wealth Management LLC increased its position in Zoetis by 0.3% during the fourth quarter. Perigon Wealth Management LLC now owns 23,581 shares of the company's stock worth $4,654,000 after buying an additional 59 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.

Zoetis Trading Down 0.1 %

NYSE ZTS traded down $0.17 on Monday, hitting $149.81. The company's stock had a trading volume of 8,667,336 shares, compared to its average volume of 2,930,192. The firm has a market cap of $68.52 billion, a PE ratio of 29.95, a PEG ratio of 2.29 and a beta of 0.85. The company's 50-day moving average is $179.92 and its 200 day moving average is $180.91. The company has a quick ratio of 2.00, a current ratio of 3.36 and a debt-to-equity ratio of 1.32. Zoetis Inc. has a 1-year low of $148.48 and a 1-year high of $201.92.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings results on Tuesday, February 13th. The company reported $1.24 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.32 by ($0.08). Zoetis had a return on equity of 51.25% and a net margin of 27.43%. The firm had revenue of $2.21 billion during the quarter, compared to the consensus estimate of $2.19 billion. During the same quarter in the previous year, the company posted $1.15 EPS. The firm's revenue was up 8.5% on a year-over-year basis. As a group, analysts predict that Zoetis Inc. will post 5.8 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Friday, April 19th will be paid a $0.432 dividend. The ex-dividend date is Thursday, April 18th. This represents a $1.73 annualized dividend and a yield of 1.15%. Zoetis's dividend payout ratio is currently 34.12%.

Insider Activity

In other Zoetis news, EVP Roxanne Lagano sold 363 shares of the stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $197.74, for a total value of $71,779.62. Following the sale, the executive vice president now directly owns 20,417 shares in the company, valued at approximately $4,037,257.58. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last ninety days, insiders sold 2,209 shares of company stock worth $408,453. 0.15% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on ZTS. The Goldman Sachs Group boosted their target price on Zoetis from $190.00 to $226.00 and gave the stock a "buy" rating in a report on Wednesday, January 17th. Stifel Nicolaus dropped their price objective on shares of Zoetis from $215.00 to $195.00 and set a "buy" rating for the company in a research note on Tuesday, April 2nd. Piper Sandler increased their target price on shares of Zoetis from $215.00 to $220.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 20th. StockNews.com downgraded shares of Zoetis from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, February 20th. Finally, Jefferies Financial Group reiterated a "buy" rating and issued a $230.00 price target on shares of Zoetis in a research note on Tuesday, December 19th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Zoetis currently has an average rating of "Buy" and an average price target of $224.88.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.